利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

454 条记录 (耗时 0.039 秒)

    TUMORS EXPRESSING IGG1 FC INDUCE ROBUST CD8 T CELL RESPONSES
    4.
    发明申请
    TUMORS EXPRESSING IGG1 FC INDUCE ROBUST CD8 T CELL RESPONSES 审中-公开
    表达IGG1 FC的肿瘤引起强烈的CD8 T细胞应答

    公开(公告)号：WO2015069745A8

    公开(公告)日：2015-06-18

    申请号：PCT/US2014064096

    申请日：2014-11-05

    申请人： UNIV TEXAS ,  UNIV YALE ,  US HEALTH

    发明人： PASARE CHANDRASHEKHAR ,  FURLAN SCOTT N ,  PALM NOAH W ,  UNNI ARUN

    IPC分类号： C12M1/38

    CPC分类号： A61K39/0011 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/572 ,  C12N5/0693 ,  C12N2510/00

    摘要： A lymphoma cell line was engineered to express surface IgGl Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgGl-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgGl-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgGl can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.

    摘要翻译： 工程化淋巴瘤细胞系以表达表面IgG1Fc。 这些肿瘤细胞被DC快速摄取，导致肿瘤衍生抗原交叉呈递至CD8T细胞。 IgG1-Fc肿瘤在体内未能生长，并且在动物模型中的预防性接种导致排斥未处理的肿瘤细胞。 此外，当用作治疗性肿瘤疫苗时，IgG1-Fc肿瘤细胞能够减缓未操作的原发性肿瘤的生长。 这证明，表达IgG1的Fc区的肿瘤对Fc受体的接合可以在没有肿瘤特异性抗原的先前知识的情况下诱导有效和保护性的抗肿瘤CD8 + T细胞应答。

    CORRELATES OF EFFICACY RELATING TO TUMOR VACCINES
    5.
    发明申请
    CORRELATES OF EFFICACY RELATING TO TUMOR VACCINES 审中-公开
    与肿瘤疫苗有关的相关性

    公开(公告)号：WO2014186596A8

    公开(公告)日：2015-06-18

    申请号：PCT/US2014038231

    申请日：2014-05-15

    申请人： NEWLINK GENETICS CORP

    发明人： ROSSI GABRIELA ,  LINK CHARLES

    IPC分类号： A61K39/00 ,  C12N5/00 ,  C12N5/07 ,  C12P21/06

    CPC分类号： A61K35/13 ,  A61K39/0011 ,  A61K48/005 ,  A61K2039/5152 ,  A61K2039/585 ,  C12N5/0693 ,  C12N9/1051 ,  C12N13/00 ,  C12N2510/00 ,  C12Y204/01087

    摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through a combination of ex vivo gene therapy protocols and cell enrichment, tumor cells are engineered to express an α (1,3) galactosyl epitope and optionally the tumor associated antigens mesothelin and carcinoembryonic antigen. After administration of the compositions of the invention to patients, the production of increased antibody titers to certain cell-surface markers, including mesothelin, calreticulin, and carcinembryonic antigen (CEA) positively correlates with an increased overall survival.

    摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案和细胞富集的组合，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位和任选的肿瘤相关抗原间皮素和癌胚抗原。 在将本发明的组合物给予患者之后，对某些细胞表面标志物（包括间皮素，钙网蛋白和癌胚抗原（CEA））的抗体滴度的增加与增加的总生存期呈正相关。

    CHIMERIC VSV VIRUS COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER
    6.
    发明申请
    CHIMERIC VSV VIRUS COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER 审中-公开
    CHIMERIC VSV病毒组合物及其用于治疗癌症的方法

    公开(公告)号：WO2015077714A1

    公开(公告)日：2015-05-28

    申请号：PCT/US2014/067137

    申请日：2014-11-24

    申请人： YALE UNIVERSITY

    发明人： VAN DEN POL, Anthony N. ,  WOLLMANN, Guido

    IPC分类号： A61K35/766 ,  A61K39/00 ,  A61P35/00 ,  C12N15/86

    CPC分类号： A61K35/766 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/007 ,  A61K35/12 ,  A61K39/205 ,  A61K45/06 ,  A61K2039/5152 ,  A61K2039/5256 ,  C12N7/00 ,  C12N7/04 ,  C12N2760/20133 ,  C12N2760/20222 ,  C12N2760/20223 ,  C12N2760/20232 ,  C12N2760/20234

    摘要： Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.

    摘要翻译： 公开了治疗癌症的方法，包括向受试者施用包含有效量的嵌合VSV病毒的药物组合物。 嵌合病毒基于VSV背景，其中VSV G蛋白被一种或多种异源病毒糖蛋白替代。 在最优选的实施方案中，VSV G蛋白被来自Lassa病毒的糖蛋白或其功能片段替代。 所得到的嵌合病毒是在脑中减毒和安全的溶瘤病毒，但仍保留足够的溶瘤活性以感染和破坏癌细胞如胶质母细胞瘤，并产生针对感染的癌细胞的免疫应答。 还提供了使用嵌合病毒作为免疫其他致病微生物的平台的方法。

    TUMORS EXPRESSING IGG1 FC INDUCE ROBUST CD8 CELL RESPONSES
    7.
    发明申请
    TUMORS EXPRESSING IGG1 FC INDUCE ROBUST CD8 CELL RESPONSES 审中-公开
    肿瘤表达IGG1 FC诱导强大的CD8细胞应答

    公开(公告)号：WO2015069745A2

    公开(公告)日：2015-05-14

    申请号：PCT/US2014064096

    申请日：2014-11-05

    申请人： UNIV TEXAS ,  UNIV YALE ,  US HEALTH

    发明人： PASARE CHANDRASHEKHAR ,  FURLAN SCOTT N ,  PALM NOAH W ,  UNNI ARUN

    IPC分类号： C12M1/38

    CPC分类号： A61K39/0011 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/572 ,  C12N5/0693 ,  C12N2510/00

    摘要： A lymphoma cell line was engineered to express surface IgGl Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgGl-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgGl-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgGl can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.

    摘要翻译： 将淋巴瘤细胞系工程化以表达IgG1 Fc。 这些肿瘤细胞被DC迅速吸收，导致肿瘤衍生的抗原与CD8T细胞的交叉表达增强。 IgG1-Fc肿瘤在体内未能生长，并且动物模型中的预防性接种导致未经操作的肿瘤细胞的排斥。 此外，当用作治疗性肿瘤疫苗时，IgG1-Fc肿瘤细胞能够减缓未操作的原发性肿瘤的生长。 这表明，通过表达IgG1的Fc区的肿瘤的Fc受体的参与可以在没有肿瘤特异性抗原的知识的情况下诱导有效和保护性的抗肿瘤CD8 + T细胞应答。